ALNY
Price
$469.57
Change
+$4.62 (+0.99%)
Updated
Oct 14, 04:59 PM (EDT)
Capitalization
60.95B
9 days until earnings call
ARWR
Price
$35.96
Change
-$0.29 (-0.80%)
Updated
Oct 14, 04:59 PM (EDT)
Capitalization
4.97B
48 days until earnings call
Interact to see
Advertisement

ALNY vs ARWR

Header iconALNY vs ARWR Comparison
Open Charts ALNY vs ARWRBanner chart's image
Alnylam Pharmaceuticals
Price$469.57
Change+$4.62 (+0.99%)
Volume$16.81K
Capitalization60.95B
Arrowhead Pharmaceuticals
Price$35.96
Change-$0.29 (-0.80%)
Volume$32.67K
Capitalization4.97B
ALNY vs ARWR Comparison Chart in %
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. ARWR commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a StrongBuy and ARWR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (ALNY: $464.95 vs. ARWR: $36.25)
Brand notoriety: ALNY: Not notable vs. ARWR: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 132% vs. ARWR: 59%
Market capitalization -- ALNY: $60.95B vs. ARWR: $4.97B
ALNY [@Biotechnology] is valued at $60.95B. ARWR’s [@Biotechnology] market capitalization is $4.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileARWR’s FA Score has 1 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • ARWR’s FA Score: 1 green, 4 red.
According to our system of comparison, both ALNY and ARWR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 3 TA indicator(s) are bullish while ARWR’s TA Score has 2 bullish TA indicator(s).

  • ALNY’s TA Score: 3 bullish, 4 bearish.
  • ARWR’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ALNY is a better buy in the short-term than ARWR.

Price Growth

ALNY (@Biotechnology) experienced а +2.87% price change this week, while ARWR (@Biotechnology) price change was -3.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.85%. For the same industry, the average monthly price growth was +14.20%, and the average quarterly price growth was +78.97%.

Reported Earning Dates

ALNY is expected to report earnings on Oct 23, 2025.

ARWR is expected to report earnings on Dec 01, 2025.

Industries' Descriptions

@Biotechnology (+0.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($60.9B) has a higher market cap than ARWR($4.97B). ALNY YTD gains are higher at: 97.590 vs. ARWR (92.819). ARWR has higher annual earnings (EBITDA): -52.51M vs. ALNY (-170.84M). ALNY has more cash in the bank: 2.86B vs. ARWR (900M). ARWR has less debt than ALNY: ARWR (353M) vs ALNY (1.3B). ALNY has higher revenues than ARWR: ALNY (2.46B) vs ARWR (573M).
ALNYARWRALNY / ARWR
Capitalization60.9B4.97B1,225%
EBITDA-170.84M-52.51M325%
Gain YTD97.59092.819105%
P/E RatioN/AN/A-
Revenue2.46B573M430%
Total Cash2.86B900M318%
Total Debt1.3B353M367%
FUNDAMENTALS RATINGS
ALNY vs ARWR: Fundamental Ratings
ALNY
ARWR
OUTLOOK RATING
1..100
8178
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
7100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3936
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALNY's Valuation (95) in the Biotechnology industry is in the same range as ARWR (100). This means that ALNY’s stock grew similarly to ARWR’s over the last 12 months.

ALNY's Profit vs Risk Rating (7) in the Biotechnology industry is significantly better than the same rating for ARWR (100). This means that ALNY’s stock grew significantly faster than ARWR’s over the last 12 months.

ARWR's SMR Rating (97) in the Biotechnology industry is in the same range as ALNY (100). This means that ARWR’s stock grew similarly to ALNY’s over the last 12 months.

ARWR's Price Growth Rating (36) in the Biotechnology industry is in the same range as ALNY (39). This means that ARWR’s stock grew similarly to ALNY’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ALNY (100). This means that ARWR’s stock grew significantly faster than ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYARWR
RSI
ODDS (%)
Bearish Trend 5 days ago
61%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
N/A
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
63%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
60%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BTEUX16.040.55
+3.52%
Baron Technology R6
FGDTX49.03N/A
N/A
Fidelity Advisor Gold M
GALLX21.84N/A
N/A
Goldman Sachs Enhanced U.S. Equity A
TRBCX212.41N/A
N/A
T. Rowe Price Blue Chip Growth
NIQCX14.43N/A
N/A
Neuberger Berman International Eq C